Report Description PharmaPoint: Colorectal Cancer — Global Drug Forecast and Market Analysis to 2025 The colorectal cancer (CRC) market considering the sales of both branded treatments and generic chemotherapy is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence and the launch and uptake of premium-priced therapies. Traditionally the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However the efficacy of these agents is limited by the insurgence of acquired resistance. Further RAS mutant patients who are not eligible to EGFR inhibitors have a lower number of available treatment options and usually receive fewer lines of treatment compared with patients with RAS wild-type disease. The CRC competitive landscape is going to experience a substantial change following the approval of pipeline agents exploiting novel mechanism...